TMA-6
2,4,6-trimethoxyamphetamine
Viewing r1 — Apr 26, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
TMA-6 (2,4,6-trimethoxyamphetamine) is a synthetic psychedelic of the substituted amphetamine class. It is a structural relative of mescaline, sharing the same three methoxy groups but arranged differently on an amphetamine backbone. It activates serotonin receptors and blocks the enzyme that breaks serotonin down, producing an amplified and prolonged psychedelic effect.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, psilocybin, mescaline +5 moreLSD, psilocybin, mescaline, DOM, DOB, DOI, 2C-B, TMA-2 show less
Alexander Shulgin independently discovered its psychedelic properties in 1964, publishing comparative potency data across the TMA series in a 1969 Nature paper.[2] He documented it as entry #162 in PiHKAL (1991),[3] calling it "one of the most rewarding and pleasurable of the methoxylated amphetamines",[4] but it never entered clinical use. Today it circulates rarely on grey-market research chemical markets and has no approved medical use.
Subjective effects include geometric visual patterns, brightened colors, euphoria, mental stimulation, and emotional intensification. The experience has a pronounced stimulant character — energized and mentally active rather than sedating — sustained across an unusually long arc that can shift between exuberance and emotional turbulence.[4] Anxiety, challenging psychological episodes, and deep fatigue from the extended duration are characteristic unsought effects.
TMA-6 produces no physical dependence, and no lethal dose has been established in any species.[5] The primary danger is pharmacological: TMA-6 activates serotonin receptors and blocks the enzyme that clears serotonin, so combining it with any serotonin-raising drug can trigger a dangerous overheating and seizure response.safety citation needed The evidence base is thin — resting almost entirely on Shulgin's self-experimentation and class-level inference.
History[edit]
Discovery
TMA-6 was first synthesized in the early 1950s as part of investigations into mescaline structural analogs.citation needed Alexander Shulgin independently discovered its psychedelic properties in 1964 through self-experimentation. Working with colleagues, he published the first systematic potency comparison of the TMA series in a 1969 Nature paper.[2]
Scientific Contribution
Shulgin documented TMA-6 as entry #162 in PiHKAL (1991),[3] describing it as "one of the most rewarding and pleasurable of the methoxylated amphetamines" and proposing it as a template for generating new analog series.[4] Its symmetric 2,4,6-substitution pattern makes it a useful structural reference point alongside mescaline and TMA-2.
Prohibition and Modern Status
TMA-6 has appeared on grey-market research chemical markets, though less commonly than TMA-2. Its detection in forensic samples prompted development of laboratory identification methods.[6][7] No clinical trials have been conducted, and it remains scheduled in multiple jurisdictions.
The name TMA-6 follows Shulgin's systematic numbering scheme for the six positional isomers of trimethoxyamphetamine. Shulgin deliberately described synthesis from phloroglucinol — a naturally occurring compound found in redwoods, tea, citrus, and apples — to keep the route accessible regardless of future precursor regulations.[4]
Chemistry[edit]
Structural Overview
TMA-6 (2,4,6-trimethoxyamphetamine) is a substituted amphetamine with three methoxy groups placed symmetrically at the 2, 4, and 6 positions of the aromatic ring.
This arrangement differs from mescaline, which carries the same three methoxy groups at the 3, 4, and 5 positions on a shorter backbone. The additional alpha-methyl group of the amphetamine scaffold gives TMA-6 greater metabolic stability and longer duration than mescaline.
| Molecular formula | C₁₂H₁₉NO₃ |
| Molecular weight | 225.28 g/mol |
Pharmacology[edit]
Mechanism of Action
TMA-6 activates serotonin receptors in the brain — the same target responsible for effects across all classical psychedelics.[5] It also inhibits MAO-A, the enzyme that breaks serotonin down in synapses.[1]safety citation needed These two actions reinforce each other: serotonin receptors are directly activated while serotonin simultaneously accumulates, producing an amplified and prolonged effect.
TMA-6 does not release dopamine or block serotonin reuptake — it is inactive at monoamine transporters.[8] This MAO-A inhibitory activity is consistent with the broader class of methoxylated amphetamines.[9][10]
Pharmacokinetics
No human pharmacokinetic data have been published. Community sources report onset at 30–90 minutes after oral ingestion[11] and total duration of 12–16 hours.[4] The prolonged duration likely reflects slow receptor release combined with the compound's own MAO-A inhibition slowing serotonin breakdown throughout.[11]inferred
Neuroscience[edit]
Where It Acts
No direct brain imaging or neural recording data exist for TMA-6. All mechanism descriptions are inferred from its pharmacology and the well-characterized neuroscience of serotonergic psychedelics.inferred As a serotonin receptor activator, TMA-6 is expected to act on prefrontal cortex neurons — the cellular trigger for psychedelic effects established across LSD, psilocybin, and mescaline.[5]
Why It Matters
The MAO-A inhibitory component sets TMA-6 apart from most classical psychedelics. It raises serotonin levels broadly across the brain — not just at the specific receptor type activated by other psychedelics — which may produce a qualitatively different experience. Whether TMA-6 promotes brain rewiring as other serotonergic psychedelics do remains unknown.
The 12–16 hour duration raises a central question: does sustained exposure produce qualitatively different neural effects compared to shorter-acting compounds, or do compensatory mechanisms attenuate the experience over time? Whether TMA-6's MAO-A inhibition produces a distinct neural signature — different patterns of network disruption or emotional processing — remains entirely untested.
Subjective Effects[edit]
TMA-6 produces a stimulating psychedelic state. The amphetamine backbone creates physical energy and mental alertness that most tryptamine psychedelics lack. The experience can range from deeply euphoric to emotionally turbulent within a single session,[4] and the unusually long duration amplifies both the rewards and the difficulties.
Compared to mescaline, TMA-6 is more potent by weight, longer-lasting, and more physically activating. Relative to the DOM family, it occupies a similar duration bracket but produces its effects through a different mechanism — both direct serotonin receptor activation and enzyme inhibition, rather than receptor affinity alone.
Effect Grid
At common doses (20–35 mg oral), the full psychedelic experience develops. Visual effects become pronounced: color alteration intensifies, surfaces exhibit visual drifting and morphing, and tracers follow moving objects. Closed-eye visuals feature geometric patterning. Thought connectivity increases substantially, producing insight and associative thinking. Emotional enhancement and empathy enhancement are reported, alongside a stimulating body state described by Shulgin as producing "great humor" and steady physical control.
Physically, stimulation is prominent — consistent with the amphetamine backbone. Peripheral vasoconstriction may produce cool extremities. Heart rate and blood pressure elevation are expected. Appetite suppression is typical.
The full 12–16 hour duration applies at this range. Sleep is not possible for the majority of the experience. Plan for no obligations for the entire day.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Tracers · Symmetrical texture repetition · Touch enhancement · Geometry · Visual breathing · Brightness alteration · Light sensitivity · Spatial disorientation · Perspective distortion · Visual diffraction · After-images · Visual morphing · Environmental patterning · Sound sensitivity · Auditory enhancement · Depth perception distortion · Visual haze / noise · Visual acuity enhancement · Visual processing acceleration · Synesthesia · Visual melting · Vestibular distortion · Peripheral vision distortion · Auditory distortion · Auditory misinterpretation · Peripheral misidentification · Visual magnification · Proprioceptive distortion · Flashbacks · Object transformations · Object activation · Visual recursion · Environmental orbism / cubism · Internal hallucinations · External hallucinations · Visual flipping · Perspective hallucinations · Auditory hallucinations · Persisting hallucinations
Visual breathing · Brightness alteration · Light sensitivity · Spatial disorientation · Perspective distortion · Visual diffraction · After-images · Visual morphing · Environmental patterning · Sound sensitivity · Auditory enhancement · Depth perception distortion · Visual haze / noise · Visual acuity enhancement · Visual processing acceleration · Synesthesia · Visual melting · Vestibular distortion · Peripheral vision distortion · Auditory distortion · Auditory misinterpretation · Peripheral misidentification · Visual magnification · Proprioceptive distortion · Flashbacks · Object transformations · Object activation · Visual recursion · Environmental orbism / cubism · Internal hallucinations · External hallucinations · Visual flipping · Perspective hallucinations · Auditory hallucinations · Persisting hallucinations
Pupil dilation · Appetite suppression · Spontaneous body sensations · Dry mouth · Body high · Nausea · Restlessness · Muscle tension · Headache · Excessive sweating · Dizziness · Tingling / electric sensations · Heart rate perception changes · Vibrations / buzzing · Sexual arousal enhancement · Trembling · Bruxism · Respiratory stimulation · Increased urination · Body schema distortion · Abnormal heartbeat · Vomiting · Motor control enhancement
Dry mouth · Body high · Nausea · Restlessness · Muscle tension · Headache · Excessive sweating · Dizziness · Tingling / electric sensations · Heart rate perception changes · Vibrations / buzzing · Sexual arousal enhancement · Trembling · Bruxism · Respiratory stimulation · Increased urination · Body schema distortion · Vomiting · Motor control enhancement
Pattern recognition enhancement · Thought acceleration · Immersion enhancement · Cognitive flexibility · Introspection enhancement · Openness enhancement · Aesthetic enhancement · Memory suppression · Analysis enhancement · Multiple thought streams · Thought loops · Creativity enhancement · Cognitive euphoria · Information processing enhancement · Motivation enhancement · Confusion · Thought disorganization · Memory fragmentation
Introspection enhancement · Openness enhancement · Aesthetic enhancement · Memory suppression · Analysis enhancement · Multiple thought streams · Thought loops · Creativity enhancement · Cognitive euphoria · Information processing enhancement · Motivation enhancement · Confusion · Thought disorganization · Memory fragmentation
Anxiety · Simultaneous emotions · Catharsis · Irritability · Dysphoria
Dysphoria
Social connection · Sociability enhancement · Communication enhancement · Depersonalization · Trust enhancement · Flow state · Identity alteration · Boundary dissolution · Ego dissolution
Trust enhancement · Flow state · Identity alteration · Boundary dissolution · Ego dissolution
Time cessation
Non-dual awareness · Entity contact
Recursive awareness
Timeline
First alerts appear as subtle mood shift, mild color brightening, and faint body awareness. The amphetamine backbone produces a gentle stimulant undercurrent before psychedelic effects become apparent.
Psychedelic effects build progressively — color enhancement deepens, visual drifting begins, and thought patterns shift toward increased connectivity. Stimulation becomes more noticeable. Mild anxiety or restlessness during this phase is common with phenethylamine psychedelics.
Full psychedelic intensity sustained over an extended plateau. Visual phenomena are active and colorful, emotional responses intensified, and cognitive patterns markedly altered. The stimulating character remains throughout.
Intensity gradually diminishes but psychedelic effects remain clearly present. Visual activity softens, emotional intensity begins to modulate, and cognitive patterns start returning toward baseline. Stimulation persists, and sleep remains impossible.
Effects continue to recede over several hours. Residual visual enhancement, mild thought alteration, and physical stimulation taper slowly. Mental clarity gradually returns, though a sense of cognitive openness may persist.
Residual mood elevation, reflective thinking, and subtle perceptual sensitivity may persist for 6–18 hours following the primary experience. Physical fatigue from the extended duration is common. Sleep quality may be disrupted for the first night.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
No lethal dose has been established for TMA-6 in any species. No human fatalities attributed solely to TMA-6 appear in the published medical literature.
Cardiovascular Effects
As an amphetamine-backbone compound with serotonin receptor activity, TMA-6 is expected to raise heart rate and blood pressure.inferred No published human cardiovascular data exist for TMA-6.
Serotonin Syndrome Risk
TMA-6's dual action as both a serotonin receptor activator and a MAO-A inhibitor creates a clinically significant risk of serotonin syndrome — a dangerous overheating and seizure response — when combined with serotonergic agents. This risk is distinctive among classical psychedelics: LSD, psilocybin, and mescaline do not inhibit MAO-A at relevant concentrations.
If the reported MAO-A inhibitory potency is accurate,[1]safety citation needed TMA-6 blocks serotonin breakdown with clinically meaningful strength at active psychedelic doses.
Psychological Risks
TMA-6 carries risk of acute anxiety, paranoia, and psychotic episodes in vulnerable individuals. One participant in Shulgin's PiHKAL described "a strange mixture of plateaus, exuberance, and strong negative feelings."[4] The 12–16 hour duration amplifies this risk: a difficult experience cannot be waited out in a single waking day, and fatigue erodes resilience over time.
Tolerance and Dependence
Tolerance develops rapidly through serotonin downregulation, consistent with all classical serotonergic psychedelics.[5] Community sources report a tolerance half-life of approximately 3 days with full reset at 7 days[11] — values consistent with the class but not verified specifically for TMA-6.inferred
Cross-tolerance extends to other serotonin-receptor psychedelics including LSD, psilocybin, mescaline, and the DOx series.[5] TMA-6 is not associated with physical dependence or compulsive use.
Drug Interactions
The critical interaction category is serotonergic potentiation, driven by TMA-6's dual serotonin receptor activation and MAO-A inhibition.
Serotonergic Agents
SSRIs (fluoxetine, sertraline, citalopram), SNRIs (venlafaxine, duloxetine), and other monoamine oxidase inhibitors carry serious serotonin syndrome risk in combination. TMA-6's own MAO-A inhibition slows metabolic clearance of co-administered serotonergic agents — adding a metabolic hazard on top of the direct pharmacological interaction.
Tryptamine psychedelics (DMT, psilocin, 5-MeO-DMT) are broken down by MAO. Combining them with TMA-6 could dramatically amplify their potency and duration — a mechanism analogous to ayahuasca but uncontrolled and unpredictable.
Stimulants
The amphetamine backbone suggests additive cardiovascular strain with other stimulants — amphetamines, cocaine, and MDMA.inferred
Lithium
Lithium combined with serotonergic psychedelics has been associated with seizures in community reports. This risk is elevated with TMA-6 given the additional MAO-A inhibition.safety citation needed
Contraindications
No substance-specific contraindication data exist. The following are inferred from pharmacological profileinferred:
- Concurrent MAO inhibitor use — serotonin syndrome risk from combined MAO-A inhibition
- Concurrent SSRI/SNRI use — serotonin syndrome risk from impaired serotonin breakdown plus reuptake inhibitor
- Personal or family history of psychotic disorders — risk of psychotic episode precipitation
- Bipolar disorder — risk of manic episode precipitation
- Heart conditions — stimulant cardiovascular effects may worsen pre-existing conditions
- Pregnancy and breastfeeding — no safety data; theoretical risk to fetal development
- Liver impairment — expected liver-mediated metabolism may result in prolonged or unpredictable drug exposure
Harm Reduction[edit]
Forms & Identification
TMA-6 is exceptionally rare on unregulated markets. Any material sold as TMA-6 carries high substitution risk — so few suppliers handle the compound that basic reagent testing may be insufficient for confirmation. Laboratory analysis is the only reliable method for confirming identity and purity for a substance this uncommon.
Practical Guidelines
- Test all material with reagent kits before use; consider laboratory analysis for positive identity confirmation
- Start at the low end of the active range and do not redose — the long onset (up to 90 minutes) and 12–16 hour duration make dose adjustment impractical and dangerous
- Prepare food, water, and comfortable clothing in advance; the experience outlasts most people's planning horizon
- Keep a sitter present for the full duration, especially at higher doses
- Avoid TMA-6 within the washout period of any serotonergic medication (SSRIs, SNRIs, monoamine oxidase inhibitors)
- Avoid all other serotonergic substances, stimulants, and lithium during and after the experience
Set & Setting
The 12–16 hour duration demands deliberate preparation. Keep a full day and the following morning clear, with no obligations until then.
A calm, familiar environment with a trusted sitter is strongly recommended, particularly given the compound's capacity to shift between euphoria and emotional difficulty within a single session. The sitter should be briefed on the extended timeline and the specific serotonin syndrome risk.
Aftercare & integration. The extended duration means the experience typically ends in exhaustion. Prioritize sleep, hydration, and light nutrition in the 24 hours following. Mood may fluctuate for one to three days as serotonin systems rebalance — this is expected and generally self-limiting.
If the experience included challenging material, journaling within the first few days can help process insights before they fade. Talking with a trusted friend or integration-oriented therapist is valuable after difficult sessions. Persistent anxiety, depersonalization, or intrusive imagery lasting beyond a week warrants professional support.
Recovery & Support
Classical psychedelics like TMA-6 are not associated with physical dependence or compulsive use patterns. Psychedelic use that avoids difficult emotions rather than explores them, or that disrupts relationships, work, or wellbeing, warrants conversation with a therapist experienced in substance use. The Fireside Project (62-FIRESIDE / 623-473-7433) provides free peer support for psychedelic experiences.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Distinguish discomfort from danger. Anxiety, nausea, and perceptual intensity are uncomfortable but expected. Seek immediate help for: rigid or jerking muscles, dangerously elevated body temperature (hot skin, confusion), rapid or irregular heartbeat, chest pain, seizure, loss of consciousness, or signs of self-harm intent.
Immediate steps:
- 1. Call emergency services if any danger signs are present
- 2. Move the person to a cool, quiet space
- 3. Do not restrain them unless there is immediate danger to self or others
- 4. If conscious and overheating, apply cool water to skin
- 5. Do not induce vomiting
What to tell the dispatcher: Name the substance (TMA-6 / trimethoxyamphetamine), the approximate dose, when it was taken, and current symptoms. Mention the MAO-A inhibitory activity — this is critical information for serotonin syndrome treatment. Good Samaritan laws in many jurisdictions protect callers who report drug emergencies.
Legal Status[edit]
TMA-6 is controlled or banned in multiple jurisdictions, primarily through scheduling of the TMA series, novel psychoactive substance legislation, or structural analog provisions.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Listed as positional isomer of TMA (DEA code 7390); Federal Analogue Act also applicable[1] |
| United Kingdom | Illegal | Covered under Psychoactive Substances Act 2016; also arguably under Misuse of Drugs Act 1971 generic phenethylamine provisions |
| Germany | Controlled (NpSG) | New Psychoactive Substances Act since November 26, 2016; production, import, and sale for human use prohibited |
| Sweden | Schedule I narcotic | Listed on Swedish narcotic schedules |
| Brazil | Controlled (F2) | F2 class of prohibited psychotropics |
| Japan | Controlled | Scheduled under drug control legislation[12] |
| Italy | Controlled | Listed on Italian drug schedules |
| Finland | Controlled | Banned December 2014 |
| Australia | Not independently verified | Status not confirmed during researchcitation needed |
| Canada | Not independently verified | Status not confirmed during researchcitation needed |
Legal status changes frequently and varies by jurisdiction. This information may be outdated. Nothing in this article constitutes legal advice — verify current status with qualified local counsel.
references
- [1]
- [2] ^abShulgin A, Sargent T, Naranjo C (1969) Structure-Activity Relationships of One-Ring Psychotomimetics — Nature doi:10.1038/221537a0
- [3]
- [4]
- [5]
- [6] ^Nieddu M, Boatto G, Pirisi MA, Azara E, Marchetti M (2008) LC-MS analysis of trimethoxyamphetamine designer drugs (TMA series) from urine samples — Journal of Chromatography B doi:10.1016/j.jchromb.2008.03.027